Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
healthday1h
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.A new study ...
Investor's Business Daily on MSN1h
Novo Nordisk Jumps After Ozempic Decidedly Beats. But 'Periodic Supply Constraints' Expected.
Novo Nordisk stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
The Ozempic boom is slowing down
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish ...
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
The best exercises you can do while using weight loss jabs
If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your body to burn more fat instead and hang on to muscle. There’s also a ...
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...